The most common side effects for dapagliflozin are hypoglycemia (especially when used in combination with a SU derivative or insulin) and genital mycotic- and urinary tract infections. These side effects are usually mild and transient. In addition dyslipidemia and increased hematocrit have been described. Long-term (side) effects of SGLT-2 inhibitors are currently being evaluated in large-scaled outcome trials. For gliclazide, hypoglycemia and blurred vision in the initiation phase of treatment (due to changes in blood glucose levels) are the most common side effects. Also gastrointestinal side-effects (nausea, vomiting, diarrhea or constipation) have been reported. Of note, the gliclazide in this study will be used at a relatively low dose (i.e. 30 mg per day) for a relatively short treatment duration (12 weeks). Therefore, also given the inclusion- and exclusion criteria of the study participants, the overall risk of hypoglycemia is believed to be low. In the unlikely case of hypoglycemia symptoms, patients will be provided with a self-monitoring blood glucose (SMBG) device and instructed to perform ambulatory blood glucose checks in case of symptoms, during the course of the study. Also, they will receive standardized diabetes education, including information regarding carbohydrate use and self-management / resolution of hypoglycemia. As in all drug intervention trials, in this study, the investigators will closely monitor patients for adverse drug and study events during the follow-up visit and by telephone consultation according to GCP. Participants can contact the research staff 24 hours a day.